Form 4 for ALT Altimmune, Inc.
Accepted 2022-03-02 00:00:00 ET · period of report 2022-02-28 · accession 0001104659-22-029462 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-02 | 2022-02-28 | ALT | Harris Matthew Scott | Chief Medical Off | M - OptEx | $1.92 | +30.0K | 41.5K | +260% | +$57.6K |
| D | 2022-03-02 | 2022-02-28 | ALT | Harris Matthew Scott | Chief Medical Off | S - Sale+OE | $7.52 | -30.0K | 11.5K | -72% | -$225.6K |
| D | 2022-03-02 | 2022-02-28 | ALT | Harris Matthew Scott | Chief Medical Off | M - OptEx | $0.00 | -30.0K | 31.4K | -49% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.0001 | 2022-02-28 | M | A | 30,000 | $1.92 | 41,545 | D | — | — | |
| 2 | Common | Common Stock, par value $0.0001 | 2022-02-28 | S | D | 30,000 | $7.52 | 11,545 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.70, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 3 | Derivative | Stock Options (option to buy) | 2022-02-28 | M | D | 30,000 | $0.00 | 31,400 | D | $1.92 · — to 2030-01-02 | 30,000 Common Stock, par value $0.0001 | (F3) Twenty-five percent of the shares underlying the option became vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date. |